These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 18212601)

  • 1. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.
    Philip NS; Carpenter LL; Tyrka AR; Price LH
    J Psychiatr Pract; 2008 Jan; 14(1):34-44. PubMed ID: 18212601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
    Erbe S; Gutwinski S; Bschor T
    Psychiatr Prax; 2012 Mar; 39(2):57-63. PubMed ID: 22189902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model of anticholinergic activity of atypical antipsychotic medications.
    Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
    Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
    Nakajima S; Takeuchi H; Fervaha G; Plitman E; Chung JK; Caravaggio F; Iwata Y; Mihashi Y; Gerretsen P; Remington G; Mulsant B; Graff-Guerrero A
    Schizophr Res; 2015 Feb; 161(2-3):429-33. PubMed ID: 25556080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y; Kim E; You M; Pikalov A; Tran QV
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.
    Barbee JG; Conrad EJ; Jamhour NJ
    J Clin Psychiatry; 2004 Jul; 65(7):975-81. PubMed ID: 15291687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of atypical antipsychotics in mood disorders.
    Weizman R; Weizman A
    Curr Opin Investig Drugs; 2001 Jul; 2(7):940-5. PubMed ID: 11757795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
    Perlis RH
    Am J Manag Care; 2007 Nov; 13(7 Suppl):S178-88. PubMed ID: 18041879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY
    J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting.
    Kasckow JW; Mulchahey JJ; Mohamed S
    J Am Med Dir Assoc; 2004; 5(4):242-8. PubMed ID: 15228634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
    Cruz N; Sanchez-Moreno J; Torres F; Goikolea JM; Valentí M; Vieta E
    Int J Neuropsychopharmacol; 2010 Feb; 13(1):5-14. PubMed ID: 19638254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of atypical antipsychotics in refractory depression and anxiety.
    Nemeroff CB
    J Clin Psychiatry; 2005; 66 Suppl 8():13-21. PubMed ID: 16336032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creating more effective antidepressants: clues from the clinic.
    Rasmussen K
    Drug Discov Today; 2006 Jul; 11(13-14):623-31. PubMed ID: 16793531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
    Shelton RC; Papakostas GI
    Acta Psychiatr Scand; 2008 Apr; 117(4):253-9. PubMed ID: 18190674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
    Chen J; Gao K; Kemp DE
    Curr Opin Psychiatry; 2011 Jan; 24(1):10-7. PubMed ID: 21088586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
    Lorenz RA; Jackson CW; Saitz M
    Pharmacotherapy; 2010 Sep; 30(9):942-51. PubMed ID: 20795849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
    Taylor DM; Cornelius V; Smith L; Young AH
    Acta Psychiatr Scand; 2014 Dec; 130(6):452-69. PubMed ID: 25283309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical antipsychotics: newer options for mania and maintenance therapy.
    Vieta E; Goikolea JM
    Bipolar Disord; 2005; 7 Suppl 4():21-33. PubMed ID: 15948764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.